Imaging Transcriptomics of Brain Functional Alterations in MS and Neuromyelitis Optica Spectrum Disorder

References

1. 1.↵
   1. Wingerchuk DM,
   2. Lennon VA,
   3. Lucchinetti CF, et al

   . The spectrum of neuromyelitis optica. Lancet Neurol 2007;6:805–15 doi:10.1016/S1474-4422(07)70216-8 pmid:17706564

   CrossRefPubMedWeb of Science
2. 2.↵
   1. Katz Sand I

   . Classification, diagnosis, and differential diagnosis of multiple sclerosis. Curr Opin Neurol 2015;28:193–205 doi:10.1097/WCO.0000000000000206 pmid:25887774

   CrossRefPubMed
3. 3.↵
   1. Patsopoulos NA,
   2. Baranzini SE,
   3. Santaniello A, et al

   ; International Multiple Sclerosis Genetics Consortium. Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. Science 2019;365:eaav7188 doi:10.1126/science.aav7188

   Abstract/FREE Full Text
4. 4.↵
   1. Satoh J,
   2. Obayashi S,
   3. Misawa T, et al

   . Neuromyelitis optica/Devic’s disease: gene expression profiling of brain lesions. Neuropathology 2008;28:561–76 doi:10.1111/j.1440-1789.2008.00915.x pmid:18410276

   CrossRefPubMedWeb of Science
5. 5.↵
   1. Estrada K,
   2. Whelan CW,
   3. Zhao F, et al

   . A whole-genome sequence study identifies genetic risk factors for neuromyelitis optica. Nat Commun 2018;9:1929 doi:10.1038/s41467-018-04332-3 pmid:29769526

   CrossRefPubMed
6. 6.↵
   1. Liu Y,
   2. Duan Y,
   3. Huang J, et al

   . Multimodal quantitative MR imaging of the thalamus in multiple sclerosis and neuromyelitis optica. Radiology 2015;277:784–92 doi:10.1148/radiol.2015142786 pmid:26043265

   CrossRefPubMed
7. 7.↵
   1. Rocca MA,
   2. Agosta F,
   3. Mezzapesa DM, et al

   . A functional MRI study of movement-associated cortical changes in patients with Devic’s neuromyelitis optica. Neuroimage 2004;21:1061–68 doi:10.1016/j.neuroimage.2003.10.013 pmid:15006674

   CrossRefPubMedWeb of Science
8. 8.↵
   1. Zou QH,
   2. Zhu CZ,
   3. Yang Y, et al

   . An improved approach to detection of amplitude of low-frequency fluctuation (ALFF) for resting-state fMRI: fractional ALFF. J Neurosci Methods 2008;172:137–41 doi:10.1016/j.jneumeth.2008.04.012 pmid:18501969

   CrossRefPubMedWeb of Science
9. 9.↵
   1. Du XF,
   2. Liu J,
   3. Hua QF, et al

   . Relapsing-remitting multiple sclerosis is associated with regional brain activity deficits in motor- and cognitive-related brain areas. Front Neurol 2019;10:1136 doi:10.3389/fneur.2019.01136 pmid:31849801

   CrossRefPubMed
10. 10.↵
    1. Liang P,
    2. Liu Y,
    3. Jia X, et al

    . Regional homogeneity changes in patients with neuromyelitis optica revealed by resting-state functional MRI. Clin Neurophysiol 2011;122:121–27 doi:10.1016/j.clinph.2010.05.026 pmid:20621555

    CrossRefPubMed
11. 11.↵
    1. Finke C,
    2. Zimmermann H,
    3. Pache F, et al

    . Association of visual impairment in neuromyelitis optica spectrum disorder with visual network reorganization. JAMA Neurol 2018;75:296–303 doi:10.1001/jamaneurol.2017.3890 pmid:29297041

    CrossRefPubMed
12. 12.↵
    1. Liu Y,
    2. Liang P,
    3. Duan Y, et al

    . Brain plasticity in relapsing-remitting multiple sclerosis: evidence from resting-state fMRI. J Neurol Sci 2011;304:127–31 doi:10.1016/j.jns.2011.01.023 pmid:21349545

    CrossRefPubMed
13. 13.↵
    1. Dobryakova E,
    2. Hafiz R,
    3. Iosipchuk O, et al

    . ALFF response interaction with learning during feedback in individuals with multiple sclerosis. Mult Scler Relat Disord 2023;70:104510 doi:10.1016/j.msard.2023.104510 pmid:36706463

    CrossRefPubMed
14. 14.↵
    1. Fornito A,
    2. Arnatkevičiūtė A,
    3. Fulcher BD

    . Bridging the gap between connectome and transcriptome. Trends Cogn Sci 2019;23:34–50 doi:10.1016/j.tics.2018.10.005 pmid:30455082

    CrossRefPubMed
15. 15.↵
    1. Richiardi J,
    2. Altmann A,
    3. Milazzo AC, et al

    ; IMAGEN Consortium. BRAIN NETWORKS: correlated gene expression supports synchronous activity in brain networks. Science 2015;348:1241–44 doi:10.1126/science.1255905 pmid:26068849

    Abstract/FREE Full Text
16. 16.↵
    1. Shen J,
    2. Yang B,
    3. Xie Z, et al

    . Cell-type-specific gene modules related to the regional homogeneity of spontaneous brain activity and their associations with common brain disorders. Front Neurosci 2021;15:639527 doi:10.3389/fnins.2021.639527 pmid:33958982

    CrossRefPubMed
17. 17.↵
    1. Thompson AJ,
    2. Banwell BL,
    3. Barkhof F, et al

    . Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 2018;17:162–73 doi:10.1016/S1474-4422(17)30470-2 pmid:29275977

    CrossRefPubMed
18. 18.↵
    1. Wingerchuk DM,
    2. Banwell B,
    3. Bennett JL, et al

    ; International Panel for NMO Diagnosis. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015;85:177–89 doi:10.1212/WNL.0000000000001729 pmid:26092914

    CrossRefPubMed
19. 19.↵
    1. Duan Y,
    2. Zhuo Z,
    3. Li H, et al

    . Brain structural alterations in MOG antibody diseases: a comparative study with AQP4 seropositive NMOSD and MS. J Neurol Neurosurg Psychiatry 2021;92:709–16 doi:10.1136/jnnp-2020-324826 pmid:33687975

    Abstract/FREE Full Text
20. 20.↵
    1. Yan CG,
    2. Wang XD,
    3. Zuo XN, et al

    . DPABI: data processing and analysis for (resting-state) brain imaging. Neuroinformatics 2016;14:339–51 doi:10.1007/s12021-016-9299-4 pmid:27075850

    CrossRefPubMed
21. 21.↵
    1. Hawrylycz MJ,
    2. Lein ES,
    3. Guillozet-Bongaarts AL, et al

    . An anatomically comprehensive atlas of the adult human brain transcriptome. Nature 2012;489:391–99 doi:10.1038/nature11405 pmid:22996553

    CrossRefPubMedWeb of Science
22. 22.↵
    1. van der Poel M,
    2. Ulas T,
    3. Mizee MR, et al

    . Transcriptional profiling of human microglia reveals grey-white matter heterogeneity and multiple sclerosis-associated changes. Nat Commun 2019;10:1139 doi:10.1038/s41467-019-08976-7 pmid:30867424

    CrossRefPubMed
23. 23.↵
    1. Martins D,
    2. Dipasquale O,
    3. Davies K, et al

    . Transcriptomic and cellular decoding of functional brain connectivity changes reveal regional brain vulnerability to pro- and anti-inflammatory therapies. Brain Behav Immun 2022;102:312–23 doi:10.1016/j.bbi.2022.03.004 pmid:35259429

    CrossRefPubMed
24. 24.↵
    1. Kister I,
    2. Chamot E,
    3. Cutter G, et al

    ; MSBase Investigators. Increasing age at disability milestones among MS patients in the MSBase Registry. J Neurol Sci 2012;318:94–99 doi:10.1016/j.jns.2012.03.017 pmid:22507751

    CrossRefPubMed
25. 25.↵
    1. Kurtzke JF

    . Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444–52 doi:10.1212/wnl.33.11.1444 pmid:6685237

    Abstract/FREE Full Text
26. 26.↵
    1. Di Filippo M,
    2. Portaccio E,
    3. Mancini A, et al

    . Multiple sclerosis and cognition: synaptic failure and network dysfunction. Nat Rev Neurosci 2018;19:599–609 doi:10.1038/s41583-018-0053-9 pmid:30158590

    CrossRefPubMed
27. 27.↵
    1. Dasdelen D,
    2. Mogulkoc R,
    3. Baltaci AK

    . Aquaporins and roles in brain health and brain injury. Mini Rev Med Chem 2020;20:498–512 doi:10.2174/1389557519666191018142007 pmid:31656150

    CrossRefPubMed
28. 28.↵
    1. Jansen M,
    2. Reinhard JF Jr.

    . Interferon response heterogeneity: activation of a pro-inflammatory response by interferon alpha and beta: a possible basis for diverse responses to interferon beta in MS. J Leukoc Biol 1999;65:439–43 doi:10.1002/jlb.65.4.439 pmid:10204571

    CrossRefPubMed
29. 29.↵
    1. Olsson T

    . Cytokines in neuroinflammatory disease: role of myelin autoreactive T cell production of interferon-gamma. J Neuroimmunol 1992;40:211–18 doi:10.1016/0165-5728(92)90135-8 pmid:1430152

    CrossRefPubMedWeb of Science
30. 30.↵
    1. Bassil R,
    2. Orent W,
    3. Elyaman W

    . Notch signaling and T-helper cells in EAE/MS. Clin Dev Immunol 2013;2013:570731 doi:10.1155/2013/570731 pmid:24324509

    CrossRefPubMed
31. 31.↵
    1. Shang Y,
    2. Smith S,
    3. Hu X

    . Role of Notch signaling in regulating innate immunity and inflammation in health and disease. Protein Cell 2016;7:159–74 doi:10.1007/s13238-016-0250-0 pmid:26936847

    CrossRefPubMed
32. 32.↵
    1. Minter LM,
    2. Turley DM,
    3. Das P, et al

    . Inhibitors of gamma-secretase block in vivo and in vitro T helper type 1 polarization by preventing Notch upregulation of Tbx21. Nat Immunol 2005;6(7):680–8 pmid:15991363

    CrossRefPubMedWeb of Science
33. 33.↵
    1. Castro K,
    2. Casaccia P

    . Epigenetic modifications in brain and immune cells of multiple sclerosis patients. Mult Scler 2018;24:69–74 doi:10.1177/1352458517737389 pmid:29307300

    CrossRefPubMed
34. 34.↵
    1. Kipp M,
    2. Wagenknecht N,
    3. Beyer C, et al

    . Thalamus pathology in multiple sclerosis: from biology to clinical application. Cell Mol Life Sci 2015;72:1127–47 doi:10.1007/s00018-014-1787-9 pmid:25417212

    CrossRefPubMed
35. 35.↵
    1. Friese MA,
    2. Schattling B,
    3. Fugger L

    . Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis. Nat Rev Neurol 2014;10:225–38 doi:10.1038/nrneurol.2014.37 pmid:24638138

    CrossRefPubMed
36. 36.↵
    1. Peterson JW,
    2. Bo L,
    3. Mork S, et al

    . Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol 2001;50:389–400 doi:10.1002/ana.1123 pmid:11558796

    CrossRefPubMedWeb of Science
37. 37.↵
    1. Minagar A,
    2. Barnett MH,
    3. Benedict RH, et al

    . The thalamus and multiple sclerosis: modern views on pathologic, imaging, and clinical aspects. Neurology 2013;80:210–19 doi:10.1212/WNL.0b013e31827b910b pmid:23296131

    Abstract/FREE Full Text
38. 38.↵
    1. Kinzel S,
    2. Weber MS

    . The role of peripheral CNS-directed antibodies in promoting inflammatory CNS demyelination. Brain Sci 2017;7:70 doi:10.3390/brainsci7070070 pmid:28640199

    CrossRefPubMed
39. 39.↵
    1. Schirmer L,
    2. Schafer DP,
    3. Bartels T, et al

    . Diversity and function of glial cell types in multiple sclerosis. Trends Immunol 2021;42:228–47 doi:10.1016/j.it.2021.01.005 pmid:33593693

    CrossRefPubMed
40. 40.↵
    1. Wardlaw JM,
    2. Smith C,
    3. Dichgans M

    . Small vessel disease: mechanisms and clinical implications. Lancet Neurol 2019;18:684–96 doi:10.1016/S1474-4422(19)30079-1 pmid:31097385

    CrossRefPubMed
41. 41.↵
    1. Thompson AJ,
    2. Baranzini SE,
    3. Geurts J, et al

    . Multiple sclerosis. Lancet 2018;391:1622–36 doi:10.1016/S0140-6736(18)30481-1 pmid:29576504

    CrossRefPubMed
42. 42.↵
    1. Tradtrantip L,
    2. Jin BJ,
    3. Yao X, et al

    . Aquaporin-targeted therapeutics: state-of-the-field. Adv Exp Med Biol 2017;969:239–50 doi:10.1007/978-94-024-1057-0_16 pmid:28258578

    CrossRefPubMed
43. 43.↵
    1. Fujihara K

    . Neuromyelitis optica spectrum disorders: still evolving and broadening. Curr Opin Neurol 2019;32:385–94 doi:10.1097/WCO.0000000000000694 pmid:30893099

    CrossRefPubMed
44. 44.↵
    1. Arnatkeviciute A,
    2. Markello RD,
    3. Fulcher BD, et al

    . Toward best practices for imaging transcriptomics of the human brain. Biol Psychiatry 2023;93:391–404 doi:10.1016/j.biopsych.2022.10.016 pmid:36725139

    CrossRefPubMed